After Hours
$
103.88
Change
0.00 0.00%
Volume
Volume 1.66m
Dec 7, 2023, 7:59 p.m.
Quotes are delayed by 20 min
Previous close
$ 105.63
$ 103.88
Change
-1.75 -1.66%
Day low
Day high
$103.73
$105.60

52 week low
52 week high
$99.14
$119.65

Market cap
$267.67B
Average volume
7.70M
P/E ratio
57.70
Rev. per Employee
$842,667
EPS
1.80
Dividend
0.77
Div yield
2.96%
Ex dividend date
12/14/23
MarketWatch News on MRK
-
Merck & Co.’s stock falls 1.6% as biggest decliner in Dow Jones Industrial Average
- Steve Gelsi
-
Merck raises quarterly dividend to 77 cents vs. 73 cents
- Ciara Linnane
-
A Golden Age of Vaccines Is Here. What It Means for You.
- Neal Templin
-
Merck paying $610 million for Caraway Therapeutics
- Steve Gelsi
-
Grab these 2 funds with rich 11%-12% yields while you can
- Michael Brush
-
Merck started at buy with $115 stock price target at Deutsche Bank
- Tomi Kilgore
-
Pharma Stocks Are Bleeding. 2 Look Like Bargains.
- Josh Nathan-Kazis
-
Moderna Reports Big Loss in Post-Pandemic Reset
- Josh Nathan-Kazis
-
Drug Stocks Keep Tanking on Earnings. Brace for More.
- Josh Nathan-Kazis
-
Merck upgraded to outperform at BMO Capital
- Tomi Kilgore
-
Merck Raises Sales Outlook After Earnings Beat
- Josh Nathan-Kazis
- Loading more headlines...
Analyst Ratings
-
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
- MarketRealist.com
-
Amgen Stock in May: A Substantial Rise
- MarketRealist.com
-
Analysts’ Recommendations for Merck, Post-1Q18 Results
- MarketRealist.com
Other News on MRK
-
Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study
- The Wall Street Journal Interactive Edition
-
The Stocks That AI Mania Left Behind
- The Wall Street Journal Interactive Edition
-
Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.
- The Wall Street Journal Interactive Edition
-
‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
- The Wall Street Journal Interactive Edition
-
These Are the Two Scientists Taking Down Cold Medicines That Don’t Work
- The Wall Street Journal Interactive Edition
-
Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion
- The Wall Street Journal Interactive Edition
-
How Research in Space Helps Doctors Treat People on Earth
- The Wall Street Journal Interactive Edition
-
Big Pharma’s Battle With the Biden Administration Could Have Legs
- The Wall Street Journal Interactive Edition
-
How Novartis’s CEO Learned From Mistakes and Got Help From an Unlikely Quarter
- The Wall Street Journal Interactive Edition
-
Expensive Drugs Targeted for First U.S. Price Negotiations
- The Wall Street Journal Interactive Edition
-
Get In on This Skin Disease Drug Before Big Pharma Does
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Apple, Amazon, Starbucks to Report in Packed Earnings Week
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Companies Brace for Supreme Court Ruling on Affirmative Action
- The Wall Street Journal Interactive Edition
-
Chamber of Commerce Challenges Government’s Drug-Price Powers
- The Wall Street Journal Interactive Edition
-
Merck Sues to Stop the IRA’s ‘Extortion’
- The Wall Street Journal Interactive Edition
-
Merck Challenges U.S. Government’s New Powers to Negotiate Drug Prices
- The Wall Street Journal Interactive Edition
-
Top Morgan Stanley M&A Banker to Join Law Firm Paul Weiss
- The Wall Street Journal Interactive Edition
-
New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on MRK
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com